Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views

被引：11

作者：

Aurilio, Gaetano ^{[1
]}

Santoni, Matteo ^{[2
]}

Massari, Francesco ^{[3
]}

Cimadamore, Alessia ^{[4
]}

Rizzo, Alessandro ^{[3
]}

Mollica, Veronica ^{[3
]}

Verri, Elena ^{[1
]}

Battelli, Nicola ^{[2
]}

Montironi, Rodolfo ^{[4
]}

机构：

[1] IEO European Inst Oncol IRCCS, Med Oncol Div Urogenital & Head & Neck Canc, I-20141 Milan, Italy

[2] Macerata Hosp, Oncol Unit, I-62100 Macerata, Italy

[3] IRCCS Azienda Osped Univ Bologna, Med Oncol, Via Albertoni 15, I-40138 Bologna, Italy

[4] United Hosp, Sch Med, Sect Pathol Anat, Polytech Univ Marche Reg, I-60126 Ancona, Italy

来源：

CANCERS | 2021年 / 13卷 / 20期

关键词：

renal cell carcinoma; histology; metabolomic profiling; therapeutics; ANTITUMOR-ACTIVITY; CANCER; INHIBITOR; GLUTAMINASE; ANTAGONIST; HYPOXIA; TARGET; MET;

D O I：

10.3390/cancers13205229

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary:& nbsp;Understanding the metabolic basis of renal cell carcinoma (RCC) has been of paramount importance in defining therapeutic management in clinical practice. Unfortunately, cancer drug resistance continues to be a major cause of treatment failure. Accordingly, developing new treatment perspectives targeting new metabolisms can contribute to overcoming the development of multidrug resistance, and thus optimize patient cure. In this review, we will define and discuss the outline of RCC metabolism, and we will describe certain therapeutic strategies targeting metabolic pathways. The PI3K/Akt signaling pathway continues to be the main target of clinical investigation in RCC patients. Data from metabolic pathways such as c-Met, GSH, and HDAC, variously targeted in combination with PI3K/Akt inhibitors, seem to offer new potential treatment opportunities for the research community. In this view, further studies are warranted.</p> </p> Background: We address novelty regarding metabolomic profiling in renal cell carcinoma (RCC) patients, in an attempt to postulate potential treatment strategies. Methods: A large-scale literature search in existing scientific websites focusing on the keywords "renal cell carcinoma", "clear cell histology", "papillary histology", "metabolomic profiling", and "therapeutics" was performed. Results: The PI3K/Akt signaling pathway is key in clear cell RCC metabolism and accordingly several drugs are presently available for routine use in clinical practice. Along this line, new treatment combinations against PI3K/Akt family members are currently under clinical investigation. On the other hand, new developed targets such as c-Met tyrosine kinase domain, glutathione (GSH) metabolism, and histone deacetylases enzymes (HDAC), as well as therapeutic strategies targeting them are currently being tested in clinical trials and here discussed. Conclusions: In RCC patients, the PI3K/Akt signaling is still the most effective targetable pathway. Targeting other metabolic pathways such as c-Met, GSH, and HDAC appears to be a promising approach and deserve further insights.</p>

引用

页数：11

共 39 条

[1] The BCL-2 arbiters of apoptosis and their growing role as cancer targets [J].

Adams, Jerry M. ;

Cory, Suzanne .

CELL DEATH AND DIFFERENTIATION, 2018, 25 (01) :27-36

[2] Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies [J].

Aggarwal, Rahul ;

Thomas, Scott ;

Pawlowska, Nela ;

Bartelink, Imke ;

Grabowsky, Jennifer ;

Jahan, Thierry ;

Cripps, Amy ;

Harb, Armand ;

Leng, Jim ;

Reinert, Anne ;

Mastroserio, Ilaria ;

Thach-Giao Truong ;

Ryan, Charles J. ;

Munster, Pamela N. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (11) :1231-1239

[3] Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma [J].

Anderson, Clarke P. ;

Matthay, Katherine K. ;

Perentesis, John P. ;

Neglia, Joseph P. ;

Bailey, Howard H. ;

Villablanca, Judith G. ;

Groshen, Susan ;

Hasenauer, Beth ;

Maris, John M. ;

Seeger, Robert C. ;

Reynolds, C. Patrick .

PEDIATRIC BLOOD & CANCER, 2015, 62 (10) :1739-1746

[4] On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models [J].

Cho, Hyejin ;

Du, Xinlin ;

Rizzi, James P. ;

Liberzon, Ella ;

Chakraborty, Abhishek A. ;

Gao, Wenhua ;

Carvo, Ingrid ;

Signoretti, Sabina ;

Bruick, Richard K. ;

Josey, John A. ;

Wallace, Eli M. ;

Kaelin, William G., Jr. .

NATURE, 2016, 539 (7627) :107-+

[5] Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma The SAVOIR Phase 3 Randomized Clinical Trial [J].

Choueiri, Toni K. ;

Heng, Daniel Y. C. ;

Lee, Jae Lyun ;

Cancel, Mathilde ;

Verheijen, Remy B. ;

Mellemgaard, Anders ;

Ottesen, Lone H. ;

Frigault, Melanie M. ;

L'Hernault, Anne ;

Szijgyarto, Zsolt ;

Signoretti, Sabina ;

Albiges, Laurence .

JAMA ONCOLOGY, 2020, 6 (08) :1247-1255

[6] Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer [J].

Choueiri, Toni K. ;

Plimack, Elizabeth ;

Arkenau, Hendrik-Tobias ;

Jonasch, Eric ;

Heng, Daniel Y. C. ;

Powles, Thomas ;

Frigault, Melanie M. ;

Clark, Edwin A. ;

Handzel, Amir A. ;

Gardner, Humphrey ;

Morgan, Shethah ;

Albiges, Laurence ;

Pal, Sumanta Kumar .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (26) :2893-+

[7] Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma [J].

Choueiri, Toni K. ;

Vaishampayan, Ulka ;

Rosenberg, Jonathan E. ;

Logan, Theodore F. ;

Harzstark, Andrea L. ;

Bukowski, Ronald M. ;

Rini, Brian I. ;

Srinivas, Sandy ;

Stein, Mark N. ;

Adams, Laurel M. ;

Ottesen, Lone H. ;

Laubscher, Kevin H. ;

Sherman, Laurie ;

McDermott, David F. ;

Haas, Naomi B. ;

Flaherty, Keith T. ;

Ross, Robert ;

Eisenberg, Peter ;

Meltzer, Paul S. ;

Merino, Maria J. ;

Bottaro, Donald P. ;

Linehan, W. Marston ;

Srinivasan, Ramaprasad .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) :181-186

[8] Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma [J].

Courtney, Kevin D. ;

Infante, Jeffrey R. ;

Lam, Elaine T. ;

Figlin, Robert A. ;

Rini, Brian I. ;

Brugarolas, James ;

Zojwalla, Naseem J. ;

Lowe, Ann M. ;

Wang, Keshi ;

Wallace, Eli M. ;

Josey, John A. ;

Choueiri, Toni K. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) :867-+

[9] Comprehensivemolecular characterization of clear cell renal cell carcinoma [J].

Creighton, Chad J. ;

Morgan, Margaret ;

Gunaratne, Preethi H. ;

Wheeler, David A. ;

Gibbs, Richard A. ;

Robertson, A. Gordon ;

Chu, Andy ;

Beroukhim, Rameen ;

Cibulskis, Kristian ;

Signoretti, Sabina ;

Vandin, Fabio ;

Wu, Hsin-Ta ;

Raphael, Benjamin J. ;

Verhaak, Roel G. W. ;

Tamboli, Pheroze ;

Torres-Garcia, Wandaliz ;

Akbani, Rehan ;

Weinstein, John N. ;

Reuter, Victor ;

Hsieh, James J. ;

Brannon, A. Rose ;

Hakimi, A. Ari ;

Jacobsen, Anders ;

Ciriello, Giovanni ;

Reva, Boris ;

Ricketts, Christopher J. ;

Linehan, W. Marston ;

Stuart, Joshua M. ;

Rathmell, W. Kimryn ;

Shen, Hui ;

Laird, Peter W. ;

Muzny, Donna ;

Davis, Caleb ;

Morgan, Margaret ;

Xi, Liu ;

Chang, Kyle ;

Kakkar, Nipun ;

Trevino, Lisa R. ;

Benton, Susan ;

Reid, Jeffrey G. ;

Morton, Donna ;

Doddapaneni, Harsha ;

Han, Yi ;

Lewis, Lora ;

Dinh, Huyen ;

Kovar, Christie ;

Zhu, Yiming ;

Santibanez, Jireh ;

Wang, Min ;

Hale, Walker .

NATURE, 2013, 499 (7456) :43-+

[10] CB-839, a selective glutaminase inhibitor, has anti-tumor activity in renal cell carcinoma and synergizes with everolimus and receptor tyrosine kinase inhibitors [J].

Emberley, E. ;

Bennett, M. ;

Chen, J. ;

Gross, M. ;

Huang, T. ;

Li, W. ;

Mackinnon, A. ;

Pan, A. ;

Rodriguez, M. ;

Steggerda, S. ;

Wang, T. ;

Zhang, J. ;

Zhang, W. ;

Parlati, F. .

EUROPEAN JOURNAL OF CANCER, 2016, 69 :S124-S124

← 1 2 3 4 →